← Eichor
Study identifier: NCT06463691 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

Condition: MCL  ·  Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.

This description comes directly from the study's public registry record.

Talk to the study team

Huilai Zhang, MD, PhD  ·  0086-22-23359337  ·  info@tjmuch.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06463691